Calliditas Therapeutics AB (publ) (CALT)

$15.575

-0.63 (-3.86%)
Rating:
Recommendation:
-
Symbol CALT
Price $15.575
Beta 1.406
Volume Avg. 0.01M
Market Cap 389.950M
Shares () -
52 Week Range 12.55-27.5
1y Target Est -
DCF Unlevered CALT DCF ->
DCF Levered CALT LDCF ->
ROE -88.01% Strong Sell
ROA -53.38% Strong Sell
Operating Margin -
Debt / Equity 102.23% Buy
P/E -
P/B 4.98 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CALT news


Ms. Renee Aguiar-Lucander
Healthcare
Biotechnology
NASDAQ Global Select

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.